Increased plasma endothelin levels in patients with male hypogonadism

Kumanov, Philip; Tomova, Analia; Кirilov, Georgi; Dakovska, L; Schinkov, A.

doi:10.1046/j.1439-0272.2002.00468.x

Cited by 10 publications

(8 citation statements)

References 25 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, 2002), we have seen that ET basal levels were increased in the patients in comparison with the healthy men. We did not establish a statistically significant correlation between the plasma levels of ET and gonadotrophins, but suggested a close relationship between testosterone and endothelin levels (Kumanov et al. , 2002).…”

Section: Discussioncontrasting

confidence: 68%

“…In our previous study in hypogonadal men (Kumanov et al, 2002), we have seen that ET basal levels were increased in the patients in comparison with the healthy men. We did not establish a statistically significant correlation between the plasma levels of ET and gonadotrophins, but suggested a close relationship between testosterone and endothelin levels (Kumanov et al, 2002). Therefore, as a second step in our investigation, we followed up the ET-1 levels before and after testosterone medication.…”

Section: Discussionmentioning

confidence: 67%

“…In our previous study in hypogonadal men (Kumanov et al. , 2002), we have seen that ET basal levels were increased in the patients in comparison with the healthy men.…”

Section: Discussionmentioning

confidence: 69%

“…Therefore, disturbances in the gonadal secretion of ET‐1 could be involved in testicular pathophysiological states. Previously, we have shown that the plasma basal levels of ET‐1 were increased in males with hypogonadism (Kumanov et al. , 2002).…”

Section: Introductionmentioning

confidence: 92%

See 3 more Smart Citations

Testosterone replacement therapy in male hypogonadism is not associated with increase of endothelin‐1 levels

2006

View full text Add to dashboard Cite

Differences in endothelin-1 (ET-1) blood plasma levels were established between healthy men and women. Little is known about vascular effects of testosterone and the interactions between sex hormones and endothelin. In order to study the relationship between ET-1 and testosterone in more detail, we have investigated 33 male patients with various forms of hypogonadism (13 with hypergonadotropic hypogonadism and 20 with hypogonadotropic hypogonadism). Fourteen age-matched healthy males served as controls. The basal ET-1 levels in patients with hypogonadism (0.96 +/- 0.12 fmol/mL) (mean +/- SEM) were significantly higher in comparison with the controls (0.44 +/- 0.04 fmol/mL), p < 0.01. Fifteen individuals of these patients were studied during the therapy with testosterone depot 250 mg i.m. The ET-1 levels decreased in this group from 0.99 +/- 0.22 to 0.78 +/- 0.14 fmol/mL at the third and to 0.76 +/- 0.25 fmol/mL at the sixth month of the medication, respectively. The differences were not significant compared with the initial levels, but the concentrations at the sixth month of the treatment were not statistically different in comparison with the ET-1 levels of the controls. There was no significant difference in lipid data between patients before and during testosterone medication, except for the high-density lipoprotein cholesterol, which decreased at the third month of the treatment. Our results show that plasma ET-1 levels in males with hypogonadism are elevated with a tendency to decrease after testosterone administration. The optimum testosterone is not associated with enhanced cardiovascular risk as far as ET-1 plasma levels and lipids are concerned.

show abstract

Section: Discussioncontrasting

confidence: 68%

Section: Discussionmentioning

confidence: 67%

“…In our previous study in hypogonadal men (Kumanov et al. , 2002), we have seen that ET basal levels were increased in the patients in comparison with the healthy men.…”

Section: Discussionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 92%

See 2 more Smart Citations

Testosterone replacement therapy in male hypogonadism is not associated with increase of endothelin‐1 levels

2006

View full text Add to dashboard Cite

show abstract

“…However, several possible mechanisms have been suggested to explain the antihypertensive effects of testosterone. Kumanov established that plasma endothelin 1 (ET1) levels are elevated in males with hypogonadism, and testosterone treatment decreases ET1 [62, 63]. Another hypothesis is that testosterone treatment of hypogonadism normalizes the contractile RhoA/Rho-kinase (ROCK) signaling pathway, which is upregulated in hypogonadal states [64].…”

Section: Hypogonadism and Atherosclerotic Risk Factorsmentioning

confidence: 99%

Connecting the Lines between Hypogonadism and Atherosclerosis

Fahed

Gholmieh

Azar

2012

International Journal of Endocrinology

View full text Add to dashboard Cite

Epidemiological studies show that atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality worldwide and point to gender differences with ageing males being at highest risk. Atherosclerosis is a complex process that has several risk factors and mediators. Hypogonadism is a commonly undiagnosed disease that has been associated with many of the events, and risk factors leading to atherosclerosis. The mechanistic relations between testosterone levels, atherosclerotic events, and risk factors are poorly understood in many instances, but the links are clear. In this paper, we summarize the research journey that explains the link between hypogonadism, each of the atherosclerotic events, and risk factors. We look into the different areas from which lessons could be learned, including epidemiological studies, animal and laboratory experiments, studies on androgen deprivation therapy patients, and studies on testosterone-treated patients. We finish by providing recommendations for the clinician and needs for future research.

show abstract